Drug safety surveillance within a strategy for the management of non-chemotherapy drug-induced neutropenia
- 182 Downloads
Background Severe non-chemotherapy drug-induced neutropenia is a rare idiosyncratic drug reaction that is considered potentially fatal. Objective To report, in terms of drug safety surveillance, the results of an institutional strategy for NCDIN. Method An observational and prospective study including all adult patients who received filgrastim for the treatment of NCDIN from June 2015 to December 2017 was carried out by hematologists and clinical pharmacists. Results 13 patients with severe NCDIN were included in the study. The median age was 51 (range 24–80) years old and 46.2% were male. Seven patients had one or more negative prognostic factors (age > 65 years, renal impairment, autoimmune diseases and/or a neutrophil count at diagnosis < 0.1 × 109 cells/L). A single drug was identified as causative in 3 patients, while in 10 cases, 2–3 drugs were considered as potentially causative. The most frequent drugs were metamizole, piperacillin/tazobactam, dexketoprofen and linezolid, among others. Seven patients developed NCDIN during their hospital stay while 6 were admitted to the emergency department. Patients were using a median of 11 drugs (IQR 8–15) at the time of diagnosis. No deaths were recorded. Conclusion Metamizole and piperacillin/tazobactam are the most common drugs linked to non-chemotherapy drug-induced neutropenia in our cohort.
KeywordsAgranulocytosis Dipyrone Febrile neutropenia Granulocyte colony-stimulating factor Pharmacovigilance
The authors would like to express their gratitude to the patients for their generous participation in this study.
This paper has not received any funding.
Conflicts of interest
The authors have no significant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
- 14.Spanish Medicines and Medical Devices Agency (AEMPS). Ministry of Health, Consumption and Social Welfare of Spain. Metamizol y riesgo de agranulocitosis [Metamizol and risk of agranulocytosis]. 2018 Oct 30 [cited 2018 Dec 28]. https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2018/NI_MUH_FV-15-2018-metamizol-agranulocitosis.htm.
- 15.Andrès E, Mourot-Cottet R, Maloisel F, et al. Idiosyncratic drug-induced neutropenia and agranulocytosis. QJM. 2017;110(5):200–305.Google Scholar